We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
-$115M
Cap. Flow
-$85.2M
Cap. Flow %
-17.03%
Top 10 Hldgs %
48.26%
Holding
330
New
47
Increased
56
Reduced
65
Closed
116

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$14.3M
2
IKT icon
Inhibikase Therapeutics
IKT
+$12.7M
3
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$10.1M
4
ABVX
Abivax
ABVX
+$9.13M
5
RVMD icon
Revolution Medicines
RVMD
+$6.34M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$27.8M
2
CYTK icon
Cytokinetics
CYTK
+$25.8M
3
KROS icon
Keros Therapeutics
KROS
+$21.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$19.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.69%
2 Financials 3.07%
3 Communication Services 1.32%
4 Technology 0.33%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYX icon
301
NCR Voyix
VYX
$1.14B
– –
-2,000
Closed -$27.1K
WST icon
302
West Pharmaceutical
WST
$24.9B
– –
-200
Closed -$60K
XAIR icon
303
Beyond Air
XAIR
$3.86M
– –
-705
Closed -$109K
XBI icon
304
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-40,000
Closed -$3.95M
ANRO icon
305
PUT
Alto Neuroscience
ANRO
$1.11B
– –
-100
Closed -$1.14K
QTTB icon
306
Q32 Bio
QTTB
$464M
– –
-64,245
Closed -$2.87M
OKLO
307
Oklo
OKLO
$8.42B
– –
-1,000
Closed -$8.09K
BKHAR
308
Black Hawk Acquisition Corp Rights
BKHAR
– –
-3,000
Closed -$3.48K
GRAL
309
GRAIL Inc
GRAL
$3.1B
– –
-4,401
Closed -$60.6K
MKDWW
310
MKDWELL Tech Inc Warrants
MKDWW
– –
-3,270
Closed -$60
ORKA
311
Oruka Therapeutics
ORKA
$5.96B
– –
-11,187
Closed -$274K
BCAX
312
Bicara Therapeutics
BCAX
$1.84B
– –
-40,440
Closed -$1.03M
TVRD
313
Tvardi Therapeutics
TVRD
$23.4M
– –
-4,430
Closed -$49.1K
AITR
314
DELISTED
AI Transportation Acquisition Corp
AITR
– –
-7,500
Closed -$78.6K
AITRR
315
DELISTED
AI Transportation Acquisition Corp Right
AITRR
– –
-7,500
Closed -$1.27K
ITCI
316
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-13,400
Closed -$980K
SYRS
317
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-45,000
Closed -$96.8K
RVNC
318
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-182,166
Closed -$945K
AGR
319
DELISTED
Avangrid, Inc.
AGR
– –
-23,000
Closed -$823K
LUMO
320
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-10,000
Closed -$38.7K
PGRU
321
DELISTED
PropertyGuru Group Limited
PGRU
– –
-20,000
Closed -$132K
TMTCR
322
DELISTED
TMT Acquisition Corp Rights
TMTCR
– –
-37,100
Closed -$10.1K
TMTC
323
DELISTED
TMT Acquisition Corp Ordinary Shares
TMTC
– –
-50,000
Closed -$562K
NVEI
324
DELISTED
Nuvei Corporation Subordinate Voting Shares
NVEI
– –
-5,000
Closed -$167K
ITI
325
DELISTED
Iteris, Inc.
ITI
– –
-10,000
Closed -$71.4K
10 11 12
13
14

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, ADAR1 Capital Management held 330 positions worth $500M, down 19% from $615M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management withdrew a net $85.2M in Q4 2024, closing 116 positions and reducing 65 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 86% a quarter earlier, followed by Financials and Communication Services.

Against the trend, ADAR1 Capital Management opened a new position in Inhibikase Therapeutics worth $16.6M.

  • ADAR1 Capital Management's largest Q4 2024 buy was Inhibikase Therapeutics: 5,103,005 shares worth $16.6M.
  • ADAR1 Capital Management added most to Zai Lab in Q4 2024, an estimated $14.3M increase.
  • ADAR1 Capital Management's biggest Q4 2024 reduction was Royalty Pharma, cutting an estimated $27.8M.
  • ADAR1 Capital Management fully exited Syndax Pharmaceuticals in Q4 2024, selling an estimated $6.74M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $500M portfolio in Q4 2024.
  • ADAR1 Capital Management opened 47 new positions and closed 116 in Q4 2024.
  • ADAR1 Capital Management's portfolio value fell 19% quarter-over-quarter to $500M.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.